ID29061A - METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53 - Google Patents

METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53

Info

Publication number
ID29061A
ID29061A IDW00200101178A ID20011178A ID29061A ID 29061 A ID29061 A ID 29061A ID W00200101178 A IDW00200101178 A ID W00200101178A ID 20011178 A ID20011178 A ID 20011178A ID 29061 A ID29061 A ID 29061A
Authority
ID
Indonesia
Prior art keywords
family
protein
composition
improve
conformation stability
Prior art date
Application number
IDW00200101178A
Other languages
English (en)
Indonesian (id)
Inventor
Heather Anne Coffey
Richard Damian Connell
Barbara Ann Foster
Farzan Rastinejad
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID29061A publication Critical patent/ID29061A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IDW00200101178A 1998-12-02 1999-12-01 METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53 ID29061A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11054298P 1998-12-02 1998-12-02

Publications (1)

Publication Number Publication Date
ID29061A true ID29061A (id) 2001-07-26

Family

ID=22333594

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101178A ID29061A (id) 1998-12-02 1999-12-01 METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53

Country Status (25)

Country Link
US (1) US20020048271A1 (fr)
EP (1) EP1137418A2 (fr)
JP (2) JP2002531396A (fr)
KR (1) KR20010086073A (fr)
CN (1) CN1329493A (fr)
AP (1) AP2001002153A0 (fr)
AU (1) AU1290700A (fr)
BG (1) BG105599A (fr)
BR (1) BR9915940A (fr)
CA (1) CA2350597A1 (fr)
EA (1) EA003326B1 (fr)
EE (1) EE200100302A (fr)
HK (1) HK1041644A1 (fr)
HR (1) HRP20010414A2 (fr)
HU (1) HUP0201215A2 (fr)
ID (1) ID29061A (fr)
IL (1) IL143094A0 (fr)
IS (1) IS5943A (fr)
NO (1) NO20012737L (fr)
OA (1) OA11722A (fr)
PL (1) PL348310A1 (fr)
TR (1) TR200101549T2 (fr)
WO (1) WO2000032175A2 (fr)
YU (1) YU35401A (fr)
ZA (1) ZA200104210B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2003000853A2 (fr) * 2001-06-20 2003-01-03 Caprion Pharmaceuticals Inc. Essais pour agregation de proteines, et utilisations
CA2454768A1 (fr) * 2001-08-10 2003-02-20 Medical Research Council Molecule
US20050221324A1 (en) * 2002-05-06 2005-10-06 Fox Michael H Genotoxicity analysis
AU2003258662A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
DE60307049T2 (de) * 2003-04-25 2007-02-08 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
US20070099950A1 (en) * 2003-11-21 2007-05-03 Jongwon Lim Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
US20080039409A1 (en) * 2003-12-24 2008-02-14 Locomogene, Inc. Method of Suppressing Cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
AU2005251735A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (fr) 2005-01-03 2011-02-16 Myriad Genetics Inc Composés bicycliques azotés et utilisation thérapeutique associée
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
MX2008000744A (es) * 2005-07-15 2008-03-10 Schering Corp Derivados de quinazolina utiles en el tratamiento del cancer.
JP5162574B2 (ja) 2006-03-22 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｄｍ２及びｐ５３間の相互作用のインヒビターとしての環式アルキルアミン誘導体
CA2644643C (fr) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibiteurs de l'interaction entre mdm2 et p53
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
WO2008008358A2 (fr) 2006-07-10 2008-01-17 Columbia University Compositions anti-cocaïne et traitement
WO2008155441A1 (fr) * 2007-06-20 2008-12-24 Marikki Laiho Activateurs et leurs applications thérapeutiques
DK2170373T3 (da) * 2007-07-10 2014-10-13 Univ Columbia Termostabilisering af proteiner
WO2009019274A1 (fr) 2007-08-06 2009-02-12 Janssen Pharmaceutica Nv Phénylènediamines substituées utilisables en tant qu'inhibiteurs de l'interaction entre mdm2 et p53
ES2639752T3 (es) 2009-02-04 2017-10-30 Janssen Pharmaceutica N.V. Inhibidores de la interacción entre MDM2 y p53
WO2011127406A2 (fr) * 2010-04-09 2011-10-13 The Brigham And Women's Hospital, Inc. Acridines en tant qu'inhibiteurs des kinases haspine et dyrk
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
EP2758403B1 (fr) 2011-09-21 2016-04-27 Inception Orion, Inc. Composés tricycliques utiles comme agents neurogènes et neuroprotecteurs
CN102660257B (zh) * 2012-05-22 2013-11-27 南京邮电大学 吩噻嗪基喹唑啉类荧光离子探针及其应用
SI3201234T1 (sl) 2014-09-30 2019-03-29 Diadem S.R.L. Protitelo, ki veže linearni epitop humanega P53 in njegove diagnostične aplikacije
CN105399670B (zh) * 2015-12-02 2018-04-17 广西中医药大学 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途
CN105418501B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
CN105399671B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
US11230578B2 (en) 2016-02-04 2022-01-25 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
CA3215564A1 (fr) * 2016-02-19 2017-08-24 Pmv Pharmaceuticals, Inc. Methodes et composes pour la restauration de la fonction du p53 mutant
CN109694358B (zh) * 2019-01-23 2022-02-08 广西师范大学 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用
WO2021061643A1 (fr) * 2019-09-23 2021-04-01 Pmv Pharmaceuticals, Inc. Méthodes et composés pour la restauration de la fonction du p53 mutant
US20210405056A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Methods for detecting mutant p53 function
US11938124B2 (en) 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
GB202111035D0 (en) * 2021-07-30 2021-09-15 Vestlandets Innovasjonsselskap As Therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
ATE327330T1 (de) * 1994-03-08 2006-06-15 Sloan Kettering Inst Cancer Rekombinante humanisierte antikörper gegen fb5
ATE354638T1 (de) * 1994-12-13 2007-03-15 Human Genome Sciences Inc Menschlicher gewebsinhibitor von metalloproteinase-4
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
EP0959877A4 (fr) * 1996-04-10 2000-08-23 Univ California Correction des defaillances genetiques a l'aide de chaperons chimiques
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
KR20000035920A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
FI105554B (fi) * 1998-05-13 2000-09-15 Galilaeus Oy Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
DE69921151T2 (de) * 1998-08-12 2005-06-02 Daiichi Pure Chemicals Co. Ltd. Fluorszierende marker
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
WO2000066125A1 (fr) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Procede de traitement du cancer a l'aide de derives de la camptothecine et de 5-fluorouracil
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
AU7847800A (en) * 1999-10-15 2001-04-30 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
US6372785B1 (en) * 2000-05-04 2002-04-16 Keith Chan, President Globoasia, Llc Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6391916B1 (en) * 2000-07-21 2002-05-21 The Hong Kong University Of Science And Technology Enediyne derivatives

Also Published As

Publication number Publication date
JP2002531396A (ja) 2002-09-24
HUP0201215A2 (en) 2002-08-28
EE200100302A (et) 2002-08-15
AU1290700A (en) 2000-06-19
KR20010086073A (ko) 2001-09-07
TR200101549T2 (tr) 2001-11-21
HRP20010414A2 (en) 2002-06-30
PL348310A1 (en) 2002-05-20
EP1137418A2 (fr) 2001-10-04
HK1041644A1 (zh) 2002-07-19
WO2000032175A2 (fr) 2000-06-08
NO20012737D0 (no) 2001-06-01
YU35401A (sh) 2005-07-19
AP2001002153A0 (en) 2001-06-30
WO2000032175A3 (fr) 2000-08-03
IS5943A (is) 2001-05-15
BR9915940A (pt) 2001-09-11
NO20012737L (no) 2001-07-09
OA11722A (en) 2005-01-25
CN1329493A (zh) 2002-01-02
CA2350597A1 (fr) 2000-06-08
EA200100502A1 (ru) 2001-12-24
IL143094A0 (en) 2002-04-21
US20020048271A1 (en) 2002-04-25
ZA200104210B (en) 2003-02-24
EA003326B1 (ru) 2003-04-24
BG105599A (en) 2002-02-28
JP2006166920A (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
ID29061A (id) METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53
ID27922A (id) KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
DE59907871D1 (de) Neue galenische zubereitungsformen von meloxicam zur oralen applikation
PT1066027E (pt) Composicao farmaceutica de topiramato
ATA69098A (de) Stoffgemisch zur topischen anwendung
DE69614690D1 (de) Herstellung von grossen hohlformigen verbundstrukturen
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
NO993068L (no) Ny forbindelsesform
ID27724A (id) Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya
PT1005328E (pt) Composicao compreendendo particulas de budesonido cristalinas finamente divididas
EE200200328A (et) Multši kompositsioon ja meetod
DK1308455T3 (da) Sammensætning omfattende anti-HER2-antistoffer
DE69915204D1 (de) Stabilisierte Proteinzusammensetzung
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
DE69937171D1 (de) Verfahren zur Herstellung von arylierten Poly-alpha-Olefinen
ID24828A (id) Komposisi-komposisi farmasi dari tizoksianida dan nitazoksanida
DE60019960D1 (de) Herstellung von isobutencopolymere
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
DE59915061D1 (de) Herstellung von strukturierten elektroden
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
ID30135A (id) Komposisi-komposisi dan metode-metode untuk mengontrol serangga-serangga
DE69900823D1 (de) Injizierbare arzneizubereitung bestehend aus paracetamol
ID22840A (id) Proses untuk penyiapan komposisi aspal
DE69913556D1 (de) Herstellung von aminen